Rinvoq Lawsuit Filed Against AbbVie By Investors Over Failure to Disclose Safety Concerns
The Rinvoq lawsuit says AbbVie executives mislead investors by failing to disclose safety concerns affecting Xeljanz would also apply to Rinvoq.
Tag Archives: AbbVie
-
-
Rinvoq Approved As Atopic Dermatitis Treatment Despite Heart, Cancer Risks
The move comes after the FDA held up Rinvoq approvals for months due to concerns it carried similar cancer and heart risks as Xeljanz.
-
Despite Side Effects of Xeljanz and Rinvoq, FDA Still Approves New Indications After Updated Warnings
The approvals come after new warnings about Xeljanz and Rinvoq side effects, which have been linked to cancer, blood clots and heart problems.
-
Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects
Cancer and heart risks linked to Rinvoq, Xeljanz and similar drugs have regulated them to secondary treatment options for rheumatoid arthritis.
-
Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz
Study claims heart risks with Olumiant are the same as those of rheumatoid arthritis patients not taking the drug, raising questions about a class-wide warning after concerns about the side effects of Xeljanz emerged
-
Xeljanz Heart Risks May Be Similar Across Other JAK Inhibitors Like Rinvoq, Oluminant: Study
More research is needed into the link between Xeljanz and heart problems to determine how much of the risk is caused by side effects of the drugs, or the condition they are designed to treat, the researchers note
-
Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects
-
Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs
-
Xeljanz Heart and Cancer Concerns May Be Impacting FDA Review of Rinvoq for Psoriatic Arthritis
-
Humira Settlement Results in $25M Payment by AbbVie Over Kickbacks, Lack of Proper Side Effects Warnings
